Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.

ABSTRACT:

Background

The proliferation of clonal cytotoxic T-cells or natural killer cells has been observed after dasatinib treatment in small studies of patients with chronic myeloid leukemia (CML).

Methods

The incidence of lymphocytosis and its association with response, survival, and side effects were assessed in patients from 3 large clinical trials. Overall, 1402 dasatinib-treated patients with newly diagnosed CML in chronic phase (CML-CP), CML-CP refractory/intolerant to imatinib, or with CML in accelerated or myeloid-blast phase were analyzed.

Results

Lymphocytosis developed in 32% to 35% of patients and persisted for >12 months. This was not observed in the patients who received treatment with imatinib. Dasatinib-treated patients in all stages of CML who developed lymp

SUBMITTER: Schiffer CA 

PROVIDER: S-EPMC5071708 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature